Results 41 to 50 of about 18,687 (213)

Boosted protease inhibitor monotherapy in HIVinfected adults: outputs from a pan-European expert panel meeting [PDF]

, 2013
While the introduction of combination highly active antiretroviral therapy (HAART) regimens represents an important advance in the management of human immunodeficiency virus (HIV)-infected patients, tolerability can be an issue and the use of several ...
Adrian Streinu-Cercel, Dan Turner, José R Arribas, Linos Vandekerckhove, Manuela Doroana, null null   +5 more
core   +4 more sources

The impact of accumulating immune adaptation in circulating strains of HIV‐1

HIV Medicine, EarlyView.
Abstract Background Mutations in human immunodeficiency virus type 1 (HIV‐1) enable the virus to evade recognition and killing by human leucocyte antigen (HLA)‐restricted T cells. These viral adaptations are specific to the HLA type of individuals and are therefore evident as HLA allele‐HIV sequence associations at the population level. Most studies of
Marwah Al‐kaabi, Alison Castley, Pooja Deshpande, Abha Chopra, David Nolan, Simon Mallal, Mina John, Silvana Gaudieri   +7 more
wiley   +1 more source

Nanoflow-nanospray mass spectrometry metabolomics reveals disruption of the urinary metabolite profiles of HIV-positive patients on combination antiretroviral therapy [PDF]

, 2017
Background: The use of combination antiretroviral therapy (cART) has substantially improved the outlook for patients with HIV infection. However, lifelong exposure to cART is also associated with adverse metabolic changes and an enhanced risk of renal ...
Abdul-Sada, Alaa, Bremner, Stephen A, Chetwynd, Andrew J, Gilleece, Yvonne, Hill, Elizabeth M, Holt, Stephen G, Samarawickrama, Amanda, Vera, Jaime H   +7 more
core   +1 more source

Longitudinal changes in plasma biomarkers of immune activation, neuronal inflammation and injury in persons with HIV initiating ART

HIV Medicine, EarlyView.
Abstract Background Data on changes in biomarkers of brain health, and their associations with cognitive function in adults commencing either dual‐ or triple‐antiretroviral therapy (ART) are sparse. Methods Plasma biomarkers (neurofilament light [NfL], glial fibrillary acidic protein [GFAP], sCD14, CXCL10, neopterin and IL‐6) were measured at baseline ...
Merle Henderson, Peter Dutey‐Magni, Carolina Herrera, Wolfgang Stöhr, Alejandro Arenas‐Pinto, Owen Swann, Amanda Heslegrave, Henrik Zetterberg, John Tregoning, Sarah Fidler, François Raffi, Andrea Calcagno, Ab Babiker, Alan Winston   +13 more
wiley   +1 more source

HIV-1 drug resistance mutations emerging on darunavir therapy in PI-naive and -experienced patients in the UK [PDF]

, 2016
BACKGROUND: Darunavir is considered to have a high genetic barrier to resistance. Most darunavir-associated drug resistance mutations (DRMs) have been identified through correlation of baseline genotype with virological response in clinical trials ...
(UKHDRD) and the UK Collaborative HIV Cohort (UK CHIC) Study Ste,, Dunn, DT, El Bouzidi, K, Mackie, N, Mbisa, JL, Phillips, AN, Pillay, D, Pozniak, AL, Sabin, CA, Tostevin, A, UK HIV Drug Resistance Database (UKHDRD) and the UK Collaborativ,, UK HIV Drug Resistance Database,, White, E   +12 more
core   +1 more source

Temporal shifts in antiretroviral therapy regimens and metabolic outcomes in people living with HIV: A systematic review and meta‐analysis

HIV Medicine, EarlyView.
Abstract Introduction Antiretroviral therapy (ART) for people living with HIV has led to dramatically reduced mortality and improved life expectancy. This achievement is accompanied by a higher risk for metabolic and other non‐communicable diseases. The role and contribution of various ART regimens to adverse metabolic outcomes are not fully understood.
Melani Ratih Mahanani, Myo Chit, Sophie Mohr, Elisenda Cama i Gibernau, Svetlana Hetjens, Volker Winkler, Hans‐Michael Steffen, Florian Neuhann   +7 more
wiley   +1 more source

Improvement of neuropsychological performances and reduction of immune-activation markers after probiotic supplementation and change of life-style in an HIV positive male: targeting the microbiota to act on gut-brain axis [PDF]

, 2017
The gut-brain axis is widely in uenced by the intestinal microbiota and dysbiosis is consequently associated with a large dysregulation of its functions. Probiotic supplementation, reducing the harmful effects of dysbiosis, has shown positive effects not
Bianchi, Luigi, Cavallari, EUGENIO NELSON, Ceccarelli, Giancarlo, Corano Scheri, Giuseppe, D'Ettorre, Gabriella, Gabriella Di Girolamo,, Martiangela, Fratino, Vassalini, Paolo, Vullo, Vincenzo   +8 more
core  

Identification of drug resistance mutations in HIV from constraints on natural evolution [PDF]

, 2015
Human immunodeficiency virus (HIV) evolves with extraordinary rapidity. However, its evolution is constrained by interactions between mutations in its fitness landscape.
Barton, John P., Butler, Thomas C., Chakraborty, Arup K., Kardar, Mehran   +3 more
core   +2 more sources

Weight gain among treatment-naïve persons with HIV starting integrase inhibitors compared to non-nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the United States and Canada. [PDF]

, 2020
IntroductionWeight gain following antiretroviral therapy (ART) initiation is common, potentially predisposing some persons with HIV (PWH) to cardio-metabolic disease.
Altoff, Keri N, Bourgi, Kassem, Crane, Heidi, Gange, Stephen J, Gill, John, Horberg, Michael A, Jenkins, Cathy A, Kirk, Gregory, Koethe, John R, Lake, Jordan, Li, Jun, Lima, Viviane D, Margolick, Joseph, Mathews, William C, Moore, Richard D, North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD), Palella, Frank, Rabkin, Charles S, Rebeiro, Peter F, Silverberg, Michael, Sterling, Timothy R, Thorne, Jennifer, Willig, Amanda, Wong, Cherise   +23 more
core   +1 more source

Pharmacokinetic Drug–Drug Interaction Potential of Oral Anticancer Drugs

Clinical Pharmacology &Therapeutics, Volume 119, Issue 6, Page 1614-1627, June 2026.
Drug–drug interaction (DDI) management is critical for safe and effective use of oral anticancer drugs (OADs). Our study objectives were to (i) compile clinically relevant pharmacokinetic (PK) DDI mechanisms for OADs and (ii) assess the prevalence of PK potential DDIs (PDDIs) in patients with advanced solid cancers.
Fatimah Alhurayri, Islam R. Younis, Shadia I. Jalal, Theodore F. Logan, Rohan Maniar, Steven M. Bray, Sara K. Quinney, Zeruesenay Desta, Todd C. Skaar, James E. Tisdale, Tyler Shugg   +10 more
wiley   +1 more source